A new study by researchers at the University of Eastern Finland shows for the first time that blood-based measurement of glial fibrillary acidic protein (GFAP) enables distinguishing patients with frontotemporal dementia from those with primary psychiatric disorders or healthy individuals.
Frontotemporal dementia is the second most common cause of dementia in the working age population. Its diagnostics are complicated by the similar symptoms presented by patients with psychiatric disorders or other neurodegenerative diseases as well as the lack of reliable diagnostic tools for differentiating these patients from each other.
A new study by researchers at the University of Eastern Finland shows for the first time that blood-based measurement of glial fibrillary acidic protein (GFAP) enables distinguishing patients with frontotemporal dementia from those with primary psychiatric disorders or healthy individuals. The levels of GFAP were significantly higher in the blood of the frontotemporal dementia patients as compared to psychiatric patients or healthy individuals. Moreover, elevated blood levels of GFAP predicted enhanced brain atrophy and faster disease progression in frontotemporal dementia patients in the follow-up.
GFAP originates from the glial cells in the central nervous system, and its increased levels reflect brain atrophy and neuroinflammation. Brain-derived biomarkers are currently mainly measured from the cerebrospinal fluid (CSF) of the patients. However, the new study now indicates that ultrasensitive single molecule array (SIMOA) is a method, which allows reliable detection of GFAP also from blood samples. This is much more practical and convenient for the patients and the health care system because it reduces the need of CSF sampling and allows wider use of biomarker measurements in clinical work. Presently, identification of suitable blood-based biomarkers for the diagnostics of neurodegenerative disorders is under intensive research.
The new study also indicated that while GFAP shows good diagnostic performance on its own, its diagnostic accuracy is further increased when combined with blood-based measurements of the neurofilament light protein from the same patients.
The now published results are expected to provide new tools for improved frontotemporal dementia diagnostics. In the future, it may be possible to distinguish patients with a neurodegenerative disease from patients with other brain diseases even at the onset of the first symptoms. On the other hand, improved diagnostics will also allow better prediction of the disease progression or even assessment of the therapeutic efficacy of future treatments. This enables intervention and support for the patients and their families at the earliest time possible.
The study was done as a collaboration between research groups of the Finnish FinFTD research network and published in the esteemed Journal of Neurology, Neurosurgery and Psychiatry (JNNP).
Katisko K, Cajanus A, Huber N, Jääskeläinen O, Kokkola T, Kärkkäinen V, Rostalski H, Hartikainen P, Koivisto AM, Hannonen S, Lehtola JM, Korhonen VE, Helisalmi S, Koivumaa-Honkanen H, Herukka SK, Remes AM, Solje E, Haapasalo A. GFAP as a biomarker in frontotemporal dementia and primary psychiatric disorders: diagnostic and prognostic performance. J Neurol Neurosurg Psychiatry. 2021 Jun 29:jnnp-2021-326487. doi: 10.1136/jnnp-2021-326487.
For further information, please contact:
Research Group Director, Adjunct Professor Eino Solje, tel. +358 40 842 5553, email: firstname.lastname@example.org
Research Director, Adjunct Professor Annakaisa Haapasalo, tel. +358403552768, email: email@example.com